Unknown

Dataset Information

0

Evaluating the potential for respiratory metagenomics to improve treatment of secondary infection and detection of nosocomial transmission on expanded COVID-19 intensive care units


ABSTRACT:

Background

Clinical metagenomics (CMg) has the potential to be translated from a research tool into routine service to improve antimicrobial treatment and infection control decisions. The SARS-CoV-2 pandemic provides added impetus to realise these benefits, given the increased risk of secondary infection and nosocomial transmission of multi-drug-resistant (MDR) pathogens linked with the expansion of critical care capacity.

Methods

CMg using nanopore sequencing was evaluated in a proof-of-concept study on 43 respiratory samples from 34 intubated patients across seven intensive care units (ICUs) over a 9-week period during the first COVID-19 pandemic wave.

Results

An 8-h CMg workflow was 92% sensitive (95% CI, 75–99%) and 82% specific (95% CI, 57–96%) for bacterial identification based on culture-positive and culture-negative samples, respectively. CMg sequencing reported the presence or absence of β-lactam-resistant genes carried by Enterobacterales that would modify the initial guideline-recommended antibiotics in every case. CMg was also 100% concordant with quantitative PCR for detecting Aspergillus fumigatus from 4 positive and 39 negative samples. Molecular typing using 24-h sequencing data identified an MDR-K. pneumoniae ST307 outbreak involving 4 patients and an MDR-C. striatum outbreak involving 14 patients across three ICUs.

Conclusion

CMg testing provides accurate pathogen detection and antibiotic resistance prediction in a same-day laboratory workflow, with assembled genomes available the next day for genomic surveillance. The provision of this technology in a service setting could fundamentally change the multi-disciplinary team approach to managing ICU infections. The potential to improve the initial targeted treatment and rapidly detect unsuspected outbreaks of MDR-pathogens justifies further expedited clinical assessment of CMg.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13073-021-00991-y.

SUBMITTER: Charalampous T 

PROVIDER: S-EPMC8594956 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4036533 | biostudies-literature
| S-EPMC4785300 | biostudies-literature
| S-EPMC5691166 | biostudies-literature
| S-EPMC8501073 | biostudies-literature
| S-EPMC3537543 | biostudies-literature
| S-EPMC7664827 | biostudies-literature
| S-EPMC2447589 | biostudies-literature
| S-EPMC3323269 | biostudies-literature
| S-EPMC8429147 | biostudies-literature
| PRJEB72027 | ENA